Trial Profile
A Pragmatic, Randomized, Parallel Group Study of the Effect on Disease Remission, Work Productivity and Tolerability of Tocilizumab in Combination With DMARDs and Individually Designed Best Practice DMARD Therapy in Patients With Early, Moderate to Severe Rheumatoid Arthritis.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 10 Nov 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 29 May 2013 Actual end date (Jan 2013) added as reported by ClinicalTrials.gov.
- 23 May 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.